Hercules Technology Growth Capital Inc Share Price Nasdaq
Equities
US4270965084
Investment Management & Fund Operators
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
19.31 USD | 0.00% | 0.00% | 0.00% |
05-17 | UBS Adjusts Price Target on Hercules Capital to $18.50 From $18, Maintains Neutral Rating | MT |
05-15 | Adaptimmune Therapeutics Enters Into $125 Million Term Loan Facility With Hercules Capital | MT |
Sales 2024 * | 509M 40.08B | Sales 2025 * | 553M 43.49B | Capitalization | 3.1B 244B |
---|---|---|---|---|---|
Net income 2024 * | 341M 26.83B | Net income 2025 * | 345M 27.15B | EV / Sales 2024 * | 6.09 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 5.62 x |
P/E ratio 2024 * |
9.2
x | P/E ratio 2025 * |
9.53
x | Employees | - |
Yield 2024 * |
8.24% | Yield 2025 * |
8.52% | Free-Float | 98.08% |
Latest transcript on Hercules Technology Growth Capital Inc
Managers | Title | Age | Since |
---|---|---|---|
Scott Bluestein
CEO | Chief Executive Officer | 45 | 16/11/10 |
Seth H. Meyer
DFI | Director of Finance/CFO | 55 | 03/03/19 |
Kiersten Botelho
CMP | Compliance Officer | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Gayle Crowell
BRD | Director/Board Member | 73 | 03/02/19 |
Robert Badavas
CHM | Chairman | 71 | 28/02/06 |
Director/Board Member | 61 | 25/09/23 |
1st Jan change | Capi. | |
---|---|---|
+12.82% | 1.77B | |
+11.45% | 1.57B | |
+16.89% | 785M | |
+9.48% | 669M | |
+27.92% | 549M | |
-4.17% | 508M | |
+34.47% | 496M | |
+73.57% | 334M | |
+27.95% | 323M |